COVID-19 Cure Update: Is Israeli Opaganib and Pluristem’s Placenta-Based Cell-Therapy the Cure

Could this be the end of the Coronavirus fear? Is this the breakthrough we have been praying for?No one has known for sure the cure of the COVID-19, scientists and researchers came out with different drugs as a cure to the coronavirus global disease. Now the Israeli have said they are testing on coronavirus patient with different drugs in search of the best drugs that will cure or help the patients to live.

The world is standing still, waiting for a miracle to happened, waiting for a form of vaccine or drugs that will cure the COVID-19 or to reduce the disease from progressing to a stage which requires mechanical ventilation.

You get all the details you need to know about Pluristem’s placenta-based cell-therapy products and Opaganib and how it has been used.

Pluristem’s placenta-based cell-therapy products Test on US Patient

After one week, six critically ill patients in Israel survived. Four of them showed improvement in respiratory parameters. Israeli-based Pluristem has treated its first American patient suffering from COVID-19 complications under the country’s compassionate use program.

Report coming out that six critically coronavirus patients in Israel who are considered high-risk for mortality were treated with Pluristem’s placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.

In Israel, the six patients were treated at three different Israeli medical centers for one week, also under a compassionate use program. They were suffering from acute respiratory failure and inflammatory complications associated with COVID-19. Four of the six patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure.

Not only had all the patients survived one week later, according to Pluristem, but four of them showed improvement in respiratory parameters and three of them are in the advanced stages of weaning from ventilators. Moreover, two of the patients with preexisting medical conditions are showing clinical recovery in addition to the respiratory improvement.

Source: www.jpost.com for more

 

Opaganib on two Patients show improvement

Israeli biopharmaceutical firm RedHill Biopharma Ltd. on Monday said that COVID-19 patients treated with its Opaganib drug in an experimental program in Israel showed improvement within days of starting treatment.

Opaganib is an investigational drug, meaning it has undergone testing, but has not yet been approved for widespread use.

The two patients showed decreased oxygen requirements, decreased levels of C-reactive proteins, indicating reduced inflammation, and increased levels of lymphocytes, a type of white blood cell.

Both patients had confirmed coronavirus infections prior to the treatment, which was carried out in unnamed Israeli hospitals. One of the patients was in the ICU and released a few days after starting treatment.

The drug was administered alongside standard of care procedures, including hydroxychloroquine background therapy, Redhill said.

“Our hope is that the unique mechanism of action of Opaganib, with both anti-viral and anti-inflammatory activity, will help COVID-19 patients by reducing lung inflammation, and thus preventing the disease from progressing to a stage which requires mechanical ventilation,” said Mark L. Levitt, RedHill’s medical director.

Sources: www.timesofisrael.com for more

We thought you should also know about

NCDC Recruitment 2020 for Surveillance Support Officers in 19 States – Register Here

5G Network: Everything you need to Know About 5th Generation Network – Spark Gist

12 of the World Worst Epidemics and Pandemics Disease in History – Spark Gist

Nigeria Center for Disease Control (NCDC) Recruitment 2020- Register Now- ncdc.gov.ng

To get more Updates 

• Subscribe to the site sparkgist.com using your Email address. Subscription is totally FREE
• LIKE our Facebook page for direct updates
• FOLLOW our Twitter News Handle for updates
• In case of any issue or  challenge or questions, Click Here